EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bisbenzimide compounds inhibit the replication of prototype and pandemic potential poxviruses

Jerzy Samolej iD, Diogo Correa Mendonca, Nicole Upfold, Marion McElwee, Mariann Landsberger iD, Artur Yakimovich iD, Arvind H Patel iD, Blair L Strang iD, Jason Mercer iD

Microbiology Spectrum · 02.04.2024 · 12 (4)

DOI: 10.1128/spectrum.04072-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 02.04.2024. Verfasst von Jerzy Samolej und 8 weiteren Autor:innen. Beteiligte Einrichtung: Insititute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Poxviridae, Smallpox. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, UKRI | Medical Research Council, UKRI | Biotechnology and Biological Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously identified the bisbenzimide Hoechst 33342 (H42) as a potent multi-stage inhibitor of the prototypic poxvirus, the vaccinia virus (VACV), and several parapoxviruses. A recent report showed that novel bisbenzimide compounds similar in structure to H42 could prevent human cytomegalovirus replication. Here, we assessed whether these compounds could also serve as poxvirus inhibitors. Using virological assays, we show that these bisbenzimide compounds inhibit VACV spread, plaque formation, and the production of infectious progeny VACV with relatively low cell toxicity. Further analysis of the VACV lifecycle indicated that the effective bisbenzimide compounds had little impact on VACV early gene expression but inhibited VACV late gene expression and truncated the formation of VACV replication sites. Additionally, we found that bisbenzimide compounds, including H42, can inhibit both monkeypox and a VACV mutant resistant to the widely used anti-poxvirus drug TPOXX (Tecovirimat). Therefore, the tested bisbenzimide compounds were inhibitors of both prototypic and pandemic potential poxviruses and could be developed for use in situations where anti-poxvirus drug resistance may occur. Additionally, these data suggest that bisbenzimide compounds may serve as broad-activity antiviral compounds, targeting diverse DNA viruses such as poxviruses and betaherpesviruses. IMPORTANCE The 2022 mpox (monkeypox) outbreak served as a stark reminder that due to the cessation of smallpox vaccination over 40 years ago, most of the human population remains susceptible to poxvirus infection. With only two antivirals approved for the treatment of smallpox infection in humans, the need for additional anti-poxvirus compounds is evident. Having shown that the bisbenzimide H33342 is a potent inhibitor of poxvirus gene expression and DNA replication, here we extend these findings to include a set of novel bisbenzimide compounds that show anti-viral activity against mpox and a drug-resistant prototype poxvirus mutant. These results suggest that further development of bisbenzimides for the treatment of pandemic potential poxviruses is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PoxviridaeSmallpoxHumansBisbenzimidazolePandemicsVaccinia virus

Stichwörter der Autor:innen

DNA replicationantiviralmpoxvaccinia virusviral transcription

Substanzen

Bisbenzimidazole

Autor:innen und Institutionen

  • Insititute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
  • MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
  • CVR-CRUSH, MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
  • Center for Advanced Systems Understanding (CASUS), Helmholtz-Zentrum Dresden-Rossendorf e.V. (HZDR), Görlitz, Germany.
  • Institute for Infection and Immunity, St George's, University of London, London, United Kingdom.

ORCID-Profile: Jerzy Samolej, Mariann Landsberger, Artur Yakimovich, Arvind H Patel, Blair L Strang, Jason Mercer

Förderung

  • Medical Research Council
  • UKRI | Medical Research Council
  • UKRI | Biotechnology and Biological Sciences Research Council

Zitieren

APA

Samolej, J., Mendonca, D. C., Upfold, N., McElwee, M., Landsberger, M., Yakimovich, A., Patel, A. H., Strang, B. L., & Mercer, J. (2024). Bisbenzimide compounds inhibit the replication of prototype and pandemic potential poxviruses. Microbiology Spectrum, 12(4). https://doi.org/10.1128/spectrum.04072-23

Vancouver

Samolej J, Mendonca DC, Upfold N, McElwee M, Landsberger M, Yakimovich A, et al. Bisbenzimide compounds inhibit the replication of prototype and pandemic potential poxviruses. Microbiology Spectrum. 2024;12(4). doi:10.1128/spectrum.04072-23

BibTeX
@article{Samolej2024,
  author = {Samolej, Jerzy and Mendonca, Diogo Correa and Upfold, Nicole and McElwee, Marion and Landsberger, Mariann and Yakimovich, Artur and Patel, Arvind H and Strang, Blair L and Mercer, Jason},
  title = {Bisbenzimide compounds inhibit the replication of prototype and pandemic potential poxviruses},
  journal = {Microbiology Spectrum},
  year = {2024},
  volume = {12},
  number = {4},
  doi = {10.1128/spectrum.04072-23}
}
Kostenlos starten →